Advertisement
Research Article Free access | 10.1172/JCI108308
Find articles by Jacobs, S. in: JCI | PubMed | Google Scholar
Find articles by Stoller, R. in: JCI | PubMed | Google Scholar
Find articles by Chabner, B. in: JCI | PubMed | Google Scholar
Find articles by Johns, D. in: JCI | PubMed | Google Scholar
Published February 1, 1976 - More info
Human subjects and rhesus monkeys receiving the antitumor agent methotrexate at the high dose levels recently introduced into clinical use (greater than 50 mg/kg) excrete significant amounts of the metabolite 7-hydroxymethotrexate. The metabolite is not detected in these species after methotrexate therapy at conventional dose levels. The evidence indicates that in primates, the in vivo conversion of methotrexate to 7-hydroxymethotrexate is a dose-dependent phenomenon, with the enzyme system(s) catalyzing the reaction having a low affinity for the drug.
Images.